Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tioxidazole
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tioxidazole is an antiprotozoal drug used primarily in the treatment of schistosomiasis, a parasitic disease caused by Schistosoma species. It is a thiazole derivative and acts as an antihelmintic agent. The mechanism of action involves interference with the energy metabolism of the parasite, leading to its death. Tioxidazole has been used in some countries for treating infections caused by Schistosoma haematobium and other related parasites.
Beyond the preview
Go deeper on tioxidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tioxidazole.